Figure 2.

High percentages of IgM positive cells in B cells at the baseline facilitate the response to anti-PD-1 treatment. (A) Comparison of the percentages of IgM⁺ B cells between R (n = 17) and NonR (n = 33) NSCLC patients receiving anti-PD-1 monotherapy at the baseline. (B) Kaplan-Meier analysis of the associations of the percentages of IgM⁺ B cells with the PFS values. (C, D) Comparison of the frequencies of PD-1⁺IgM⁺ B cells (C) and PD-L1⁺IgM⁺ B cells (D) between R (n = 17) and NonR (n = 33) NSCLC patients at the baseline. The Wilcoxon test was used to analyze the differences between two groups. Survival curves were plotted by using the Kaplan-Meier method with the median as the cutoff to define the high and low group. P-values were calculated by the log-rank statistics in Kaplan-Meier analyses. ***P < 0.001, ns, P > 0.05.